-+ 0.00%
-+ 0.00%
-+ 0.00%

Belite Bio wins FDA Priority Review for tinlarebant in Stargardt disease NDA

PUBT·08/11/2026 20:02:34
Listen to the news
Belite Bio wins FDA Priority Review for tinlarebant in Stargardt disease NDA
  • Belite Bio mendapat penerimaan FDA untuk NDA tinlarebant bagi Stargardt Disease Type 1, disertai Priority Review.
  • Tenggat keputusan PDUFA ditetapkan 12 Februari 2027; jika disetujui, tinlarebant berpotensi menjadi terapi pertama untuk STGD1.
  • Pengajuan didukung uji fase 3 DRAGON, menunjukkan penurunan 35,7% laju pertumbuhan lesi atrofi retina versus plasebo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608111601PRIMZONEFULLFEED9807987) on August 11, 2026, and is solely responsible for the information contained therein.